Seemal F Awan, Amarendra Pegu, Larisa Strom, Cristina A Carter, Cynthia S Hendel, LaSonji A Holman, Pamela J Costner, Olga Trofymenko, Renunda Dyer, Ingelise J Gordon, Ro Shauna S Rothwell, Somia P Hickman, Michelle Conan-Cibotti, Nicole A Doria-Rose, Bob C Lin, Sarah O'Connell, Sandeep R Narpala, Cassandra G Almasri, Cuiping Liu, Sungyoul Ko, Young D Kwon, Aryan M Namboodiri, Janardan P Pandey, Frank J Arnold, Kevin Carlton, Jason G Gall, Peter D Kwong, Edmund V Capparelli, Robert T Bailer, Adrian B McDermott, Grace L Chen, Richard A Koup, John R Mascola, Emily E Coates, Julie E Ledgerwood, Martin R Gaudinski
BACKGROUNDBroadly neutralizing monoclonal antibodies (bNAbs) represent a promising strategy for HIV-1 immunoprophylaxis and treatment. 10E8VLS and VRC07-523LS are bNAbs that target the highly conserved membrane-proximal external region (MPER) and the CD4-binding site of the HIV-1 viral envelope glycoprotein, respectively.METHODSIn this phase 1, open-label trial, we evaluated the safety and pharmacokinetics of 5 mg/kg 10E8VLS administered alone, or concurrently with 5 mg/kg VRC07-523LS, via s.c. injection to healthy non-HIV-infected individuals...
April 8, 2024: JCI Insight